Pharma's Market

SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

LATEST FROM OUR BLOGS

» More

- 10 Dividend Picks For Your Portfolio: Chief Investors

MORE HEADLINES

» Markets | Economy | Companies

- China Overcapacity Worsening, EU Chamber Warns

PHARMA'S MARKET VIDEO

» More

Sebelius on Vaccines

24 Nov 2009

Discussing whether a new $487M investment from the government will help speed up the production of the most important vaccines, with Kathy Sebelius, Health & Human Services secretary and CNBC's Mike Huckman.

The New Formula for Faster Vaccines

24 Nov 2009

Novartis is opening on Tuesday the country's first plant to produce flu vaccines using cell cultures. These vaccines are faster, better and cheaper to make than egg-based methods, reports CNBC's Mike Huckman.

Novartis Opens 1st US Plant for Flu Vaccine

24 Nov 2009

Cholesterol Drug Battle: Niaspan vs. Zetia 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Cardiologist Grades Cholesterol Drug Study

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiovascular Medicine at The Cleveland Clinic, shares his reaction with CNBC's Mike Huckman.

Merck's Cholesterol Drugs Under Pressure

16 Nov 2009

A new study is putting Merck's cholesterol drugs under pressure today, reports CNBC's Mike Huckman, with Ken Frazier, Merck Global Human Health president.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

CNBC ON DIGG

Lilly's Side-Effect Slip-Up

Published: Thursday, 23 Jul 2009 | 3:33 PM ET

Text Size

By: Mike Huckman
Reporter

I'm betting somebody's blood pressure at Eli Lilly [LLY Loading... () ] headquarters in Indianapolis today went through the roof.

At 10:45 a.m. ET the company put out a press release announcing that the Food and Drug Administration had approved LLY's drug Forteo for a new use. (I can't provide a link to the release and I'll explain why later.) It wasn't earth-shattering or stock-moving news and we left it alone. In fact, I quickly permanently deleted the one the company sent to me.

That is, until two hours and ten minutes later, when this press release popped into my inbox. Now, they got my attention.

If you'll click on the link you'll see that the company had to send out a boldface correction to the earlier Forteo release. What was their mistake? In the "Important Safety Information" section of the release (y'know, the part that no one reads) it said, "Forteo can cause serious side effects including an increase in blood pressure when you change positions." Alright. Well, according to the reissued press release, apparently Forteo can cause a decrease in blood pressure.

Oops!

Lilly has taken down the original release containing the error from its website. Someone's blood pressure has probably also come down.

Questions? Comments? and follow me on Twitter at mhuckman